



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

November 9, 2022

Peter Blume-Jensen, M.D., Ph.D.  
Chief Executive Officer and President  
Acrivon Therapeutics, Inc.  
480 Arsenal Way, Suite 100  
Watertown, MA 02472

**Re: Acrivon Therapeutics, Inc.  
Amendment No. 2 to Registration Statement on Form S-1  
Exhibit Nos. 10.5, 10.6, and 10.7  
Filed November 8, 2022  
File No. 333-267911**

Dear Dr. Blume-Jensen:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance